Literature DB >> 3265879

Regulation of gene expression of M-, G-, GM-, and multi-CSF in normal and malignant hematopoietic cells.

W Oster1, A Lindemann, R Mertelsmann, F Herrmann.   

Abstract

Colony stimulating factors (CSFs) are produced by a variety of cell types, including T-lymphocytes (T cells) and mononuclear phagocytes; both cell types are known to cooperatively interact to elaborate CSFs, although the specific cellular source of CSF species and mechanisms of intercellular communications in this regard are poorly understood. In this report, we investigate the specific origin of various CSF species in peripheral blood mononuclear cells (PBMC), purified T-lymphocyte and monocyte (Mo) populations. Furthermore, we assess the conditions required for stimulation of purified cell cultures to express CSF messenger RNAs (mRNAs) and proteins. In the absence of exogenous activation stimuli, human PBMC, T cells and Mo failed to produce transcripts for CSF for macrophages (M-CSF or CSF-1), for granulocytes (G-CSF), for granulocytes/macrophages (GM-CSF), and for multilineage CSF (multi-CSF or Il-3). However, after stimulation with phorbol myristate acetate (PMA) and phytohemagglutinin (PHA), mRNAs for M-, G-, GM-CSF, and multi-CSF became detectable in PBMC as early as 6 hours after initiation of cultures. Identical culture conditions resulted in synthesis of G-, and M-CSF mRNA by Mo, whereas T-lymphocytes produced GM-CSF and multi-CSF mRNA. More physiologically, when Mo were activated with interferon (IFN)-gamma or tumor necrosis factor-alpha (TNF-alpha) and T-lymphocytes were stimulated in an Mo-independent pathway, that is via triggering of the 50 kd sheep erythrocyte receptor protein employing monoclonal antibodies (mo ab) to the Tll-2- and Tll-3- defined epitopes, similar kinetics of mRNA expression were obtained. Similarly, when interleukin-1 (Il-1) receptive T cells were stimulated with Il-1, T cells transcribed functionally active GM-CSF and multi-CSF. Maximum peak activity of GM-, G-, and M-CSF protein secretion was identical for all CSF species investigated, and occurred in culture 48-72 hours after specific induction. Constitutive expression of CSFs not found in unactivated normal hematopoietic cells was, however, frequently observed in blast cell populations of patients with acute myeloblastic leukemia. Of 49 AML samples, 15 revealed G-CSF transcripts; 11, GM-CSF mRNA; and 6 samples synthesized M-CSF mRNA. Employing specific bioassays, 12 of 15 G-CSF-mRNA-producing cell populations, 8 of 11 GM-CSF-mRNA-producing cell populations, and 1 of 6 M-CSF-mRNA-synthesizing samples, demonstrated release of the respective functionally active CSFs into their culture supernatants.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265879

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  9 in total

Review 1.  Polypeptides controlling hematopoietic cell development and activation. I. In vitro results.

Authors:  F Herrmann; R Mertelsmann
Journal:  Blut       Date:  1989-03

Review 2.  The role of colony-stimulating factors in acute leukemia.

Authors:  F Herrmann; E Vellenga
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control.

Authors:  W Oster; N A Cicco; H Klein; T Hirano; T Kishimoto; A Lindemann; R H Mertelsmann; F Herrmann
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  Granulocyte-macrophage colony-stimulating factor can stimulate macrophage proliferation via persistent activation of Na+/H+ antiport. Evidence for two distinct roles for Na+/H+ antiport activation.

Authors:  S J Vallance; C P Downes; E J Cragoe; A D Whetton
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

5.  Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.

Authors:  Hisaharu Shikata; Yoshihiro Yakushijin; Jun Yamanouchi; Taichi Azuma; Masaki Yasukawa
Journal:  Int J Clin Oncol       Date:  2013-02-05       Impact factor: 3.402

Review 6.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

7.  A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.

Authors:  Erin E Thacker; Masaharu Nakayama; Bruce F Smith; R Curtis Bird; Zhanat Muminova; Theresa V Strong; Laura Timares; Nikolay Korokhov; Ann Marie O'Neill; Tanja D de Gruijl; Joel N Glasgow; Kenzaburo Tani; David T Curiel
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

Review 8.  The role of VEGF in normal and neoplastic hematopoiesis.

Authors:  Hans-Peter Gerber; Napoleone Ferrara
Journal:  J Mol Med (Berl)       Date:  2002-12-14       Impact factor: 4.599

9.  PLZF is a regulator of homeostatic and cytokine-induced myeloid development.

Authors:  Sergei Doulatov; Faiyaz Notta; Kim L Rice; Louise Howell; Arthur Zelent; Jonathan D Licht; John E Dick
Journal:  Genes Dev       Date:  2009-09-01       Impact factor: 11.361

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.